Site is Being Upgraded

Lifespan extension therapy: Panaxynol, isolated from American ginseng,  may increase life span via up-regulation of its target gene BubR1, 17/January/2017, 10.02 pm

Activation of the PD-1 pathway for Pain therapy: Sildenafil [Phosphodiesterase-5 inhibitor], a drug used in the treatment of erectile dysfunction and pulmonary arterial hypertension,  increases the expression of PD-L1, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gene, 17/January/2017, 1.29 pm
January 17, 2018
Vitamin-based therapy for Stroke: Vitamin-D/Cholecalciferol attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits via up regulation of its target genes BDNF and NAMPT, 18/January/2018, 11.34 am
January 18, 2018
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Lifespan extension therapy: Panaxynol, isolated from American ginseng,  may increase life span via up-regulation of its target gene BubR1


What is known? 

Panaxynol has been shown to inhibit cardiac hypertrophy. However, the exact mechanism of action is far from clear.


From Research Findings to Therapeutic Opportunity: 

This study suggests, for the first time, that Panaxynolby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

[easy_payment currency=”USD”]

Figure 1. A therapeutic mix encompassing Panaxynol may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

Figure 2. The chemical structure of Panxynol.

 

Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing Panaxynol or its analogues, either alone or in combination with other drugs may be used to extend the lifespan of an individual (fig. 1).


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How a pharmaceutical mix encompassing Panaxynol increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Lifespan extension therapy: Panaxynol, isolated from American ginseng,  may increase life span via up-regulation of its target gene BubR1, 17/January/2017, 10.02 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.